Oxford BioMedica PLC

131 articles with Oxford BioMedica PLC

• 

  BioForest Hotbed: The Fastest-Growing Life Science Market

  3/14/2019

  A recent report by the U.S. Bureau of Labor Statistics and CBRE Research identified Seattle—which happens to be the BioSpace Bio Forest Hotbed—as the fastest-growing life science market in the top 10 from 2014 to 2017, with a greater than 17-percent growth.
• 

  Oxford Biomedica Teams With Microsoft to Use AI to Improve Gene Therapies

  3/13/2019

  The goal is to improve the yield and quality of next-generation gene therapy vectors—typically viruses—using artificial intelligence (AI) and machine learning.

• Oxford Biomedica announces R&D collaboration with Microsoft to improve gene and cell therapy manufacturing using the intelligent cloud and machine learning

  3/12/2019

  Cell and gene therapy has the potential to transform medicine, providing long-term and potentially curative treatment options for a wide range of diseases.

• Oxford Biomedica notes Axovant's update on Phase 2 trial of AXO-Lenti-PD gene therapy in Parkinson’s disease

  3/11/2019

  Axovant reported 3-month data from the first dose cohort in the open-label, dose-escalation portion of the ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD for the treatment of Parkinson’s disease.

• Kymriah® (tisagenlecleucel, formerly CTL019) receives European Commission Approval

  8/28/2018

  Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today notes that the European Commission (EC) has approved the Novartis CAR-T cell therapy, Kymriah® (tisagenlecleucel, formerly CTL019).

• 

  Axovant Licenses Gene Therapy for Parkinson’s Disease from Oxford BioMedica

  6/6/2018

  Axovant Sciences, one of Vivek Ramaswamy’s biotech startups, is taking another shot, this time at Parkinson’s disease.

• Oxford BioMedica and Axovant Sciences enter into a $842.5 Million Exclusive Worldwide Licence Agreement for OXB-102 for the Treatment of Parkinson’s Disease

  6/6/2018

  ~ Conference call for analysts to be held at 2:30pm BST / 9:30am ET (see details below)

• 

  Oxford BioMedica Wins $105M Gene Therapy Contract From Bioverativ

  2/15/2018

  The deal includes a licence to use OXB's LentiVector Enabled technology and access to its industrial-scale manufacturing technology.

• Oxford BioMedica Announces A £2 Million Two-Year Collaboration Co-Funded By Innovate UK

  8/14/2017

• Oxford BioMedica Forges A $100 Million+ CAR-T Supply Deal With Novartis AG

  7/7/2017

• Oxford BioMedica PLC Notes Findings On CTL019 From Phase II JULIET Study Presented At The 14th Meeting Of International Conference On Malignant Lymphoma (ICML)

  6/15/2017

• Orchard Therapeutics Announces Strategic Alliance With Oxford BioMedica PLC

  11/29/2016

• Oxford BioMedica PLC Announces Expanded Collaboration And Licence With Immune Design Corporation

  3/7/2016

• Oxford BioMedica PLC Release: Interim Results For The Six Months Ended 30 June 2015

  8/27/2015

• Oxford BioMedica PLC Interim Management Statement

  5/7/2015

• Oxford BioMedica PLC Appoints Daniel Soland As Non-Executive Director To The Board

  5/7/2015

• Oxford BioMedica PLC Announces That A Summary Of The 12 Month And Three Year Follow Up Data From The Phase I/II Study With Prosavin Was Presented At The AANS Conference In The U.S.

  5/5/2015

• Oxford BioMedica PLC Secures $50 Million

  5/1/2015

• Oxford BioMedica PLC To Present at 3rd Annual Regen Med Investor Day

  3/20/2015

• Oxford BioMedica PLC Director's Share Purchase

  3/16/2015